Prothena

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Prothena reports robust earnings, advances Alzheimer's treatments with promising results

Prothena's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements in neurodegenerative diseases, and promising results in key programs like PRX012 and Birtamimab.
Challenges include navigating reimbursement changes, dosing complexities, and ensuring accelerated approval pathways for Alzheimer's treatments.
Opportunities lie in leveraging financial strength for pipeline expansion, upcoming data releases, innovative treatment approaches, and establishing leadership in niche disease areas.
Overall, Prothena's strategic focus on innovative therapies and deep understanding of disease mechanisms position the company for continued growth and clinical success.

Prothena reports robust financials and promising clinical advancements in Q4

Prothena's Q4 2023 earnings call highlighted strong financials, progress in key clinical programs, and promising results in movement disorder studies.
While facing challenges in patient enrollment and dose optimization, the company's focus on specialized therapies and patient-centric development positions it well for future growth.
Opportunities lie in optimizing dosing strategies, enhancing treatment efficacy, and leveraging exposure response data to drive innovation and improve therapeutic outcomes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Prothena stock catapulted Thursday after the company's Roche-partnered Parkinson's treatment showed promise in a midstage study. The post Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease appeared first on Investor's Business Daily.

Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced results from PADOVA study conducted by partner Roche investigating prasinezumab in early-stage Parkinson's disease.

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?

PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.

Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus

Prothena (PRTA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to earnings of $0.38 per share a year ago.

Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the third quarter and first nine months of 2024 and provided business highlights.

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Axsome Therapeutics

AstraZeneca

Novavax

Theravance Biopharma

Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.

Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its third quarter and first nine months of 2024 financial results on Tuesday, November 12, 2024.

Prothena to Report Third Quarter 2024 Financial Results on November 12

Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer.

Prothena Announces Leadership Team Updates

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that members of its senior management team will participate in two upcoming investor conferences in September 2024.

Prothena to Participate in Upcoming Healthcare Conferences

What Makes Prothena (PRTA) a New Buy Stock

Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.

Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues

Prothena (PRTA) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of a loss of $1.01 per share. This compares to loss of $1.03 per share a year ago.

Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates

DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the second quarter and first six months of 2024 and provided business highlights.

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its second quarter and first six months of 2024 financial results on Thursday, August 8, 2024.

Prothena to Report Second Quarter 2024 Financial Results on August 8

Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?

Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?

Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.

Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million.

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.

Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses

Prothena (PRTA) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $0.89 per share a year ago.

Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the first quarter of 2024 and provided business highlights.

News for Prothena Stock (PRTA)